Prometheus Laboratories @prometheuslab

In a recent American Gastroenterological Association (AGA) position statement they recognized that in order to optimize therapy for IBD patients, treating providers need more objective data on how each individual patient will respond to a particular medication. PredictrPK is the…

Today, we announced a collaboration with @Celltrioninc to validate and expand the upper limit of quantification for Anser® IFX therapeutic drug monitoring testing for patients receiving subcutaneous infliximab. Read the announcement: prometheuslabs.com/collaboration-…

More physicians like Dr. Rouster are using the data from Respondr TNF to help predict whether their IBD patients will respond to infliximab or adalimumab, and identify patients where response needs to be more closely monitored so they can intervene quickly with dose optimization…

In Case You Missed It at DDW | A prospective study of IBD patients treated with infliximab (IFX) maintenance therapy found that precision-guided dosing, which reports predicted IFX trough levels with alternative dosing strategies AND patient drug clearance, may help providers…

PredictrPK is now available for vedolizumab and ustekinumab during the maintenance phase of therapy! Along with previously available tests for infliximab and adalimumab these unique tests offer personalized dosing optimization strategies for biologic drugs in support of…

Did You Know? | The average IBD-related hospital stay costs about $33,000! Patients with unoptimized treatment are more likely to experience flares and require hospitalization. PredictrPK is the only test that gives dosing guidance to help ensure patients have drug levels…

According to a study published in Pharmaceutics this year, 81% of healthcare providers surveyed indicated PredictrPK ADA helped them select the optimal adalimumab dose and/or interval for their inflammatory bowel disease patients. Read more about this study:…

Did You Know? | Accelerated pre-therapy clearance can predict the risk for a colectomy within 6 months in patients with acute severe ulcerative colitis. 🔗 Understand your patient’s pre-therapy clearance and likelihood of response to anti-TNFs with Respondr TNF:…

Even IBD patients with a low to moderate likelihood of responding to infliximab can achieve sustained remission with anti-TNF therapy when dosing is optimized early. To optimize therapy early using objective evidence, providers can use Respondr to guide therapy selection,…

We are thrilled to announce the publication of a new paper in Pharmaceutics that highlights the clinical application of PredictrPK ADA from the EMPOWER clinical experience study. Tools like PredictrPK ADA are revolutionizing how healthcare providers make treatment decisions…

Our continuum of precision-guided testing enables providers to tailor every decision along the IBD patient journey to each individual. Learn more at prometheuslabs.com. #Gastroenterology #GITwitter #IBD #IBDTwitter #GI #GIHealth

Did You Know? | Overweight and obese patients with Crohn’s disease who initiate treatment with adalimumab are more likely to have lower trough concentrations and experience treatment failure: journals.lww.com/ajg/abstract/2… Early optimized precision-guided dosing with PredictrPK may…

Accelerated pre-therapy clearance (>0.326 L/day) and genetic risk for anti-TNF immunogenicity significantly impact therapy response. Before starting an IBD patient on an anti-TNF such as infliximab or adalimumab, use Respondr to predict their likelihood of response. Learn more:…

Accelerated pre-therapy clearance (>0.326 L/day) and genetic risk for anti-TNF immunogenicity significantly impact therapy response. Before starting an IBD patient on an anti-TNF such as infliximab or adalimumab, use Respondr to predict their likelihood of response. Learn more:…

Less than 2 weeks to go until San Diego Take Steps, presented by Prometheus Laboratories. This year, it’s being held Sunday, June 1 at 10 a.m. at Liberty Station in Point Loma. If a loved one suffers from Inflammatory Bowel Disease and you’re in the San Diego area, sign up to…

Less than 2 weeks to go until San Diego Take Steps, presented by Prometheus Laboratories. This year, it’s being held Sunday, June 1 at 10 a.m. at Liberty Station in Point Loma. If a loved one suffers from Inflammatory Bowel Disease and you’re in the San Diego area, sign up to…

Less than 2 weeks to go until San Diego Take Steps, presented by Prometheus Laboratories. This year, it’s being held Sunday, June 1 at 10 a.m. at Liberty Station in Point Loma. If a loved one suffers from Inflammatory Bowel Disease and you’re in the San Diego area, sign up to…

Less than 2 weeks to go until San Diego Take Steps, presented by Prometheus Laboratories. This year, it’s being held Sunday, June 1 at 10 a.m. at Liberty Station in Point Loma. If a loved one suffers from Inflammatory Bowel Disease and you’re in the San Diego area, sign up to…

Less than 2 weeks to go until San Diego Take Steps, presented by Prometheus Laboratories. This year, it’s being held Sunday, June 1 at 10 a.m. at Liberty Station in Point Loma. If a loved one suffers from Inflammatory Bowel Disease and you’re in the San Diego area, sign up to…

Less than 2 weeks to go until San Diego Take Steps, presented by Prometheus Laboratories. This year, it’s being held Sunday, June 1 at 10 a.m. at Liberty Station in Point Loma. If a loved one suffers from Inflammatory Bowel Disease and you’re in the San Diego area, sign up to…